Biopharma | May 01, 2026
Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Subscribe To Our Newsletter & Stay Updated
